PHARVARIS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.6 USD | -3.95% |
|
-3.21% | -19.43% |
| Apr. 15 | Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating | MT |
| Apr. 12 | Pharvaris Files Mixed Shelf | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.13B 1.21B |
|---|---|---|---|---|---|
| Net income 2024 * | -115M -124M | Net income 2025 * | -136M -146M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 282M 303M | Net cash position 2025 * | 161M 173M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-9.12
x | P/E ratio 2025 * |
-8.69
x | Employees | 82 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharvaris N.V.
More recommendations
More press releases
| 1 day | -3.95% | ||
| 1 week | -3.21% | ||
| Current month | -8.09% | ||
| 1 month | +0.76% | ||
| 3 months | -25.07% | ||
| 6 months | +22.29% | ||
| Current year | -19.43% |
1 week
22.48
25.50
1 month
17.5725.50
Current year
17.5733.00
1 year
7.9333.00
3 years
1.7733.00
5 years
1.7742.86
10 years
1.7742.86
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Lesage
FOU | Founder | 63 | 15-09-29 |
| Founder | 65 | 15-09-29 | |
Stefan Abele
CTO | Chief Tech/Sci/R&D Officer | 55 | Nov. 14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 15-09-29 | |
David Meeker
CHM | Chairman | 69 | 20-12-31 |
Robert Glassman
BRD | Director/Board Member | 62 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 22.6 | -3.95% | 55,488 |
| 24-05-02 | 23.53 | -4.23% | 78,777 |
| 24-05-01 | 24.57 | -0.08% | 114,135 |
| 24-04-30 | 24.59 | +4.86% | 67,926 |
| 24-04-29 | 23.45 | +0.43% | 49,577 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotes
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
20.98
EUR
Average target price
31.03
EUR
Spread / Average Target
+47.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.43% | 1.22B | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- PHVS Stock
